Tag Archives: Treatment

Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)–May 8, 2020 — AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or… Read More »

How to treatment for acne

Health information and advice to stop the spread of coronavirus. Treatment for acne depends on how severe it is. It can take several months of treatment before acne symptoms improve. If you have a few blackheads, whiteheads and spots, a pharmacist should be able to tell you on how to treat them. They’ll usually give… Read More »

WHO says it will engage US to make remdesivir coronavirus treatment more widely available

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus attends a daily press briefing on COVID-19, the disease caused by the novel coronavirus, at the WHO heardquaters in Geneva on March 11, 2020. Fabrice Coffrini | AFP | Getty Images The World Health Organization said Monday it will speak with the U.S. government and Gilead Sciences on… Read More »

FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma

FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma Print this page HORSHAM, Pa., May 1, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro™ is approved in four regimens… Read More »

FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer Regardless of Biomarker Status

Print this page London UK — 29 April 2020 — Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend… Read More »

Potential new HIV treatment developed at UNMC

A novel means to prevent HIV infection was developed at UNMC that could allow people with or at risk of acquiring the virus to take medicines once a year. The advance has the potential to eliminate complications that arise from missing doses of life-saving medicines, according to the study published Monday in “Nature Materials,” a leading peer-reviewed… Read More »